Tweets
- Tweets, current page.
- Tweets & replies
- Media
You blocked @FiercePharma
Are you sure you want to view these Tweets? Viewing Tweets won't unblock @FiercePharma
-
Spectrum's Rolontis, angling to rival Amgen's Neulasta, hit with FDA rejection over manufacturing 'deficiencies'https://www.fiercepharma.com/manufacturing/spectrum-s-rolontis-angling-to-rival-amgen-s-neulasta-sent-back-by-fda …
Thanks. Twitter will use this to make your timeline better. UndoUndo -
GSK again scores $235M in 'skinny label' case, but court admits it's 'unclear what Teva even did wrong'https://www.fiercepharma.com/pharma/court-reaffirms-235m-judgement-for-gsk-against-generic-manufacturer-teva-skinny-label-case …
Thanks. Twitter will use this to make your timeline better. UndoUndo -
Sanofi and Regeneron solidify Dupixent TV ad lead, topping July pharma spenders again, trailed by AbbVie and Novo Nordiskhttps://www.fiercepharma.com/marketing/sanofi-and-regeneron-solidify-dupixent-tv-lead-topping-july-pharma-spenders-again-trailed …
Thanks. Twitter will use this to make your timeline better. UndoUndo -
While Novo's GLP-1 meds post big gains, the company is still looking to create an insulin 'revolution,' CEO sayshttps://www.fiercepharma.com/pharma/as-novo-nordisk-s-wegovy-works-to-unlock-obesity-company-sets-stage-for-insulin-revolution …
Thanks. Twitter will use this to make your timeline better. UndoUndo -
AstraZeneca chief Soriot lends GlaxoSmithKline's Walmsley CEO wisdom, support as activist investors press for changehttps://www.fiercepharma.com/pharma/astrazeneca-chief-soriot-lends-glaxosmithkline-s-walmsley-ceo-wisdom-support-amid-investor …
Thanks. Twitter will use this to make your timeline better. UndoUndo -
How's Amgen's key KRAS launch looking? It's too early for meaningful sales, but expectations are riding highhttps://www.fiercepharma.com/marketing/how-s-amgen-s-key-kras-launch-looking-it-s-early-days-but-lumakras-gaining-steam-execs …
Thanks. Twitter will use this to make your timeline better. UndoUndo -
Pfizer, Flynn face revived U.K. antitrust accusations of 'unfairly high' prices on epilepsy drughttps://www.fiercepharma.com/pharma/pfizer-flynn-face-revived-u-k-antitrust-accusation-antiepileptic-drug-excessive-pricing …
Thanks. Twitter will use this to make your timeline better. UndoUndo -
Sanofi, Regeneron stop Libtayo-chemo lung cancer trial early on strong survival datahttps://www.fiercepharma.com/pharma/sanofi-regeneron-stop-libtayo-chemo-lung-cancer-trial-early-strong-survival-data …
Thanks. Twitter will use this to make your timeline better. UndoUndo -
Regeneron's COVID-19 antibodies rake in $2.6B, reflecting their market dominance and blowing away estimateshttps://www.fiercepharma.com/pharma/regeneron-s-covid-19-antibodies-rake-2-6b-second-quarter-reflecting-treatment-s-new …
Thanks. Twitter will use this to make your timeline better. UndoUndo -
Boehringer Ingelheim packs new tech into cell-culture plant set for October starthttps://www.fiercepharma.com/manufacturing/boehringer-ingelheim-eyes-finish-line-its-fourth-large-scale-cell-culture-facility …
Thanks. Twitter will use this to make your timeline better. UndoUndo -
'The kidney medicine': Bayer touts Kerendia's blockbuster potential as its pharma group swings back to growthhttps://www.fiercepharma.com/pharma/kidney-medicine-bayer-touts-kerendia-potential-as-pharma-swings-back-to-growth …
Thanks. Twitter will use this to make your timeline better. UndoUndo -
Moderna, citing variants and waning immunity, expects COVID-19 boosters to become a fact of lifehttps://www.fiercepharma.com/pharma/moderna-citing-variants-and-waning-immunity-expects-covid-19-boosters-to-become-a-fact-life …
Thanks. Twitter will use this to make your timeline better. UndoUndo -
Social media mavens join SK Life Science's latest epilepsy awareness campaign to promote zero seizures goalhttps://www.fiercepharma.com/marketing/social-media-mavens-join-sk-life-science-s-latest-epilepsy-awareness-campaign-to-promote …
Thanks. Twitter will use this to make your timeline better. UndoUndo -
Amgen splashes $550M and plans to hire hundreds in Tarheel State manufacturing pushhttps://www.fiercepharma.com/manufacturing/another-industry-move-to-tarheel-state-as-amgen-choses-north-carolina-for-its-new …
Thanks. Twitter will use this to make your timeline better. UndoUndo -
Pfizer, Moderna and Alnylam flag pharma labor shortage in Massachusetts—and the people bottleneck doesn't stop therehttps://www.fiercepharma.com/manufacturing/pfizer-moderna-and-alnylam-flag-pharma-labor-shortage-ma-and-people-bottleneck-doesn …
Thanks. Twitter will use this to make your timeline better. UndoUndo -
Amgen vows to fight after IRS demands $3.6B in back taxes—and a bigger bill could be on the wayhttps://www.fiercepharma.com/pharma/irs-wants-amgen-to-cough-up-3-6b-back-taxes-but-it-s-not-budging-yet …
Thanks. Twitter will use this to make your timeline better. UndoUndo -
AstraZeneca's launch plan for first-in-class lupus med Saphnelo centers on patient-designed support programhttps://www.fiercepharma.com/marketing/astrazeneca-preps-first-new-lupus-drug-10-years-simplicity-message-for-often-discordant …
Thanks. Twitter will use this to make your timeline better. UndoUndo -
Bristol Myers pulls an Istodax lymphoma use 10 years after FDA accelerated approvalhttps://www.fiercepharma.com/marketing/bristol-myers-pulls-istodax-lymphoma-use-10-years-after-fda-accelerated-approval …
Thanks. Twitter will use this to make your timeline better. UndoUndo -
BeiGene lays plans for 'flagship' biologics plant and R&D center in New Jerseyhttps://www.fiercepharma.com/marketing/beigene-lays-plans-for-flagship-biologics-plant-and-r-d-center-nj …
Thanks. Twitter will use this to make your timeline better. UndoUndo -
'Erratic' FDA and inconsistent drug decisions put doctors off new meds: surveyhttps://www.fiercepharma.com/marketing/erratic-fda-and-inconsistent-drug-decisions-confound-specialty-physicians-changing …
Thanks. Twitter will use this to make your timeline better. UndoUndo
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.